Man 'lucky' not to have killed stranger he stabbed
A 56-year-old man who launched an unprovoked knife attack on a stranger was fortunate not to have killed him, a judge has said.
James Lammas, of Belvedere Road, Ilfracombe, stabbed a 33-year-old man multiple times on the high street in the north Devon town in September 2024.
At Exeter Crown Court, Lammas admitted wounding with intent and was jailed for three years and four months.
Judge Anna Richardson said "such an unprovoked attack would be terrifying" for the victim.
The court heard Lammas admit he "went a bit far" as he went to help a girl who he thought the victim was attacking or having a heated row with.
The victim needed hospital treatment and said he was suffering panic attacks and flashbacks.
The court also heard Lammas, who has complex post-traumatic stress disorder (PTSD), had drunk alcohol and used cannabis and Valium before the incident.
More news stories for Devon
Listen to the latest news for Devon
Follow BBC Devon on X, Facebook and Instagram. Send your story ideas to spotlight@bbc.co.uk.
HM Courts & Tribunals Service
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
10 hours ago
- Health Line
What Are the Complications and Long-Term Risks of Meningitis
Meningococcal meningitis can lead to serious complications, such as hearing loss, scarring, or even amputation. Getting treatment early can prevent these outcomes. Meningitis is a condition characterized by swelling of the lining of the brain and spinal cord. It can be caused by viruses, bacteria, or fungi. Meningococcal meningitis occurs when the bacterium Neisseria meningitidis infects the meninges (tissues around the brain and spinal cord). Neisseria meningitidis can also infect the bloodstream. Meningococcal meningitis and bloodstream infections are two common types of meningococcal disease. An infection of the meninges can cause a dangerous buildup of pressure on the brain. Symptoms of infection may include: headache stiff neck confusion sensitivity to light high fever nausea skin rash vomiting Main complications of meningitis Meningococcal disease is fatal in about 10 to 15 people out of every 100 receiving a diagnosis, according to the Centers for Disease Control and Prevention (CDC). The disease may lead to long-term complications in about 20% of those with the condition. Among the possible complications of meningococcal disease are: chronic pain scarring amputation hearing impairment vision impairment motor function impairment post-infection inflammatory syndromes arthritis post-traumatic stress disorder (PTSD) anxiety depression Some complications of meningococcal disease that require immediate medical attention are: septic shock seizures purpura fulminans (skin rash and possible organ failure) hydrocephalus (fluid buildup on the brain) cerebral venous sinus thrombosis (stroke) Waterhouse-Friderichsen syndrome (bleeding into the adrenal glands) subdural empyema (pus between layers of the brain's protective tissue) Bacteremia and septicemia One type of meningococcal disease is an infection of the tissues around the brain and spinal cord (meningococcal meningitis). Neisseria meningitidis can also infect the bloodstream, resulting in bacteremia or septicemia. Meningococcal septicemia is a dangerous form of bloodstream infection. The bacteria multiply and release toxins that can damage blood vessel linings. Bleeding into the skin or organs may occur. A characteristic dark purple rash may develop in the later stages. Other symptoms may include: fatigue vomiting cold hands and feet chills diarrhea rapid breathing severe aches or pains in the muscles, joints, chest, or belly. This form of infection also requires immediate care and can cause some of the most serious complications of meningococcal disease, such as: necrosis (skin death) hearing loss deafness seizures amputation skin scarring impaired blood flow to the organs heart failure Diagnosis and treatment Diagnosing meningococcal disease can be a challenge because early symptoms look like other conditions. When a doctor suspects meningococcal disease, they can test for the presence of bacteria in cerebrospinal fluid or blood. Getting a sample of spinal fluid requires a lumbar puncture procedure. Antibiotics are the mainstay of treatment. Doctors typically start antibiotic treatment as soon as they suspect meningococcal disease to reduce the risk of serious complications. In some cases, someone with meningococcal disease will require hospitalization. Some types of care they might receive include: intensive care unit (ICU) admission and medications to help maintain a stable blood pressure, especially if it drops too low due to severe infection intravenous (IV) fluids and rehydration breathing and airway support blood transfusions wound and skin care How common are meningitis outbreaks? According to the CDC, there were 438 confirmed and probable cases of meningococcal disease in the United States in 2023. The recent rise in cases has been mostly linked to the serogroup Y strain of Neisseria meningitidis, one of several strains that can cause meningococcal disease. Serogroup Y has been spreading more frequently in recent years, contributing to localized outbreaks. Some groups are more at risk than others. Infants, teens, and young adults tend to have higher rates of developing an infection, as do people with certain medical conditions or those living in close quarters like college dorms or military barracks. Outbreaks also tend to occur in communities with lower vaccination rates or limited access to preventive care. That's why it's so important to recognize the signs, respond quickly to symptoms, and stay up to date with recommended vaccines, especially for people at a higher risk. Vaccines are available that help protect against different types of meningococcal disease, including the strains most often linked to outbreaks, such as serogroups A, C, W, Y, and B.
Yahoo
13 hours ago
- Yahoo
Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers include new pipeline products and psychedelic therapeutics. Discover market insights, competitor analysis, and strategic opportunities in the 7MM market. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast" report has been added to report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments. The PTSD market across the 7MM was valued at $1.2 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 15.8%, reaching $5.4 billion by 2034. A key driver of growth will be the launch of eight late-stage pipeline products, including the first psychedelic therapeutics for Scope Overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, symptoms, diagnosis, and disease management. Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PTSD market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD. The most promising candidates in late-stage development are profiled. Analysis of the current and future market competition in the 7MM PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 7MM PTSD therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PTSD therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Company Coverage: GSK Eli Lilly and Co Otsuka Pharmaceutical Co Ltd Pfizer Seelos Therapeutics Ananda Scientific Lykos Therapeutics Idorsia Pharmaceutical Compass Pathways Transcend Therapeutics Neuphoria Therapeutics Key Topics Covered: 1. Preface2. Executive Summary3. Disease Overview3.1. Overview of PTSD3.2. Pathophysiology of PTSD3.3. Classification of PTSD3.4. PTSD SWOT Analysis4. Epidemiology4.1. 12-Month Total Prevalent Cases of PTSD, Men and Women, Ages ? 18 Years, 2024?344.2. Age-Specific 12-Month Total Prevalent Cases of PTSD, Men and Women, 20244.3. Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ?18 Years, 20244.4. 12-Month Total Prevalent Cases of PTSD by Disease Status, Men and Women, Ages ?18 Years, 20244.5. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD4.6. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Disease Status4.7. Sources Used to Forecast the 12Month Total Prevalent Cases of PTSD by Military Status4.8. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD4.9. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD by Disease Status5. Current Treatment Options5.1. Treatment Paradigm5.2. Current Treatment Options5.3. Product Profile: Pfizer's Zoloft/Besitran/Lustral (sertraline)5.4. Product Profile: GSK's Paxil/Deroxat/Seroxat/Aropax (paroxetine)5.5. Product Profile: Eli Lilly's Prozac (fluoxetine)5.6. Product Profile: Pfizer's Effexor XR/Effexor/Effexor XL/Vandral (venlafaxine)5.7. Product Profile: Pfizer's Minipress/Hypovase (prazosin)5.8. Patient Flow: PTSD in 2024 Across 7MM6. Unmet Needs and Opportunities6.1. Unmet Needs in PTSD6.2. New Therapeutic Options with Improved Efficacy6.3. Increase Access to Psychotherapy6.4. Treatment Options with Improved Side-Effect Profiles6.5. More consistent diagnostic and treatment guidelines7. R&D Strategies7.1. Trends in Clinical Trial Design in PTSD7.2. Regulatory Challenges for Psychedelic Treatments7.3. Timeline of Regulatory Challenges for Lykos Therapeutics7.4. Trends in Deal-Making in PTSD8. Pipeline Assessment8.1. PTSD Pipeline Overview8.2. Late-Stage Pipeline Agents for PTSD8.3. Product Profile: Otsuka Pharmaceutical's Rexulti (brexpiprazole)8.4. Product Profile: Neuphoria Therapeutics' BNC-2108.5. Product Profile: Idorsia Pharmaceutical's Quviviq (daridorexant)8.6. Product Profile: Ananda Scientific's Nantheia ATL5 (cannabidiol)8.7. Product Profile: Transcend Therapeutics' TSND-201 (methylone)8.8. Product Profile: Lykos Therapeutics' midomafetamine hydrochloride8.9. Product Profile: Seelos Therapeutics' Ereska (ketamine hydrochloride)8.10. Product Profile: Compass Pathways' COMP360 (psilocybin)8.11. PTSD: Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. PTSD Market Forecast9.2. Market Drivers and BarriersFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Boy and girl sentenced for killing dog walker, 80
A 15-year-old boy and a 13-year-old girl have been sentenced for killing an 80-year-old man out walking his dog in a park. Bhim Kohli died the day after he was assaulted in Franklin Park, yards from his home in Braunstone Town, Leicestershire, on 1 September last year. The boy, who racially abused Mr Kohli before slapping him in the face with a slider shoe, was sentenced to seven years in custody at Leicester Crown Court on Thursday. The girl, who encouraged the assault and laughed as she filmed it on her phone, was given a youth rehabilitation order of three years and made subject to a six month curfew. Both were convicted of manslaughter. Follow BBC Leicester on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@ or via WhatsApp on 0808 100 2210. Police told of racist attack before man killed 'He revelled in his hard man reputation': What led to a teen killing an elderly dog walker Teens who killed 80-year-old 'utterly disgusting' HM Courts & Tribunals Service
